公司资料
Humacyte 股价、新闻与催化剂
- 股票代码:
- HUMA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.64 USD (-5.75%)
收盘价
最后更新: 2026年8月21日
309M USD
市值
股价为何变动
The latest monitored company update is “Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions.” The corresponding closing-price reaction is not yet available.
公司概览
Bioengineered Human Tissue Platform
Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale.
SYMVESS
SYMVESS is an FDA-approved acellular tissue-engineered vessel for urgent arterial repair after extremity vascular trauma. It is Humacyte's first commercial product and validates the broader tissue platform.
Hemodialysis Access
The Phase 3 V012 study compared the vessel with autologous arteriovenous fistulas for hemodialysis access in women. Positive results form the basis for a planned supplemental BLA.
Coronary Program
Humacyte's coronary tissue-engineered vessel is being developed as an off-the-shelf conduit for coronary artery bypass grafting. The FDA has cleared the IND for a first-in-human Phase 2a study.
Broader Vascular Applications
Additional development areas include peripheral artery disease, pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.
未来催化剂
- Initiation of a Phase 2a study of the coronary tissue-engineered vessel in coronary artery bypass grafting in the third quarter of 2026.
- Submission of a supplemental BLA for the acellular tissue-engineered vessel in hemodialysis access in the second half of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。